News and price dashboard

Starfighters Space drops on a publicity item

FJET fell 9.2% on a day when the only news was promotional: the company said it will fly and display its F-104 Starfighters at the NASA-sponsored MAX POWER expo and airshow at Kennedy Space Center on November 7-8, with flight operations director Piercarlo Ciacchi piloting. Neither article links the announcement to the share move. The GuruFocus write-up on the same news is where the substance is, and it is unflattering: no meaningful revenue so price-to-sales is effectively nil, a GF Score of 14 out of 100, return on equity of -156.7%, and insiders selling $7.6 million of stock over twelve months with no buying at all. Offsetting that, the balance sheet is clean, with a current ratio of 11.94 and debt-to-equity of 0.02 on a $56 million market cap. The company's fleet came from Italy's retired F-104 inventory after 2004 and operates out of Kennedy and Midland, Texas, supporting hypersonic testing, microgravity work and pilot training.

SpaceX Q3 beat drives the tape

SPCX rose 7.8% and was the most active name on the day at 215.5 million shares. Q3 revenue was $14.58 billion, up 161% year on year against a Street figure near $12.87 billion, with EPS of $0.35 versus $0.13 expected and net income of $4.4 billion, a $5.5 billion swing from last year's $1.1 billion loss. Adjusted EBITDA was $8.81 billion. The mix is the story: the Super Intelligence segment did $7.6 billion, up 830% year on year and up $5 billion sequentially, making AI the largest revenue line for the first time at roughly 52% of sales, though $608 million of that came from the mid-quarter Cursor acquisition. Connectivity was $5.25 billion, up 69%, with 13.6 million Starlink consumer subscribers after 1.6 million net adds, ARPU of $69 a month and enterprise/government revenue up 91%. Space was $1.8 billion, up 84% sequentially but only 6% year on year, and swung to a $7 million operating loss from $259 million of income a year ago. Twelve customer launches in the quarter, 113 year to date, and Flight 14 reached orbit and deployed V3 satellites.

The capex and quality-of-earnings caveats

Management guided Q1 2027 revenue to $33-37 billion against a FactSet consensus near $22 billion, and is targeting a $100 billion annualised run-rate by December, with Musk floating $500 billion to $1 trillion of ARR by end-2027 and calling it a "crazy note" himself. The offset is spending. Q3 capex was $19.6 billion and Q4 is guided to $35-40 billion, roughly double. Nine-month operating cash flow of $13.1 billion fell short of capex by about $35 billion; cash stands at $51-53 billion against $38.8 billion of debt and finance leases. Part of the margin was one-off: Connectivity's 55% gross margin included about three points from tariff refunds, and management said Q4 should look more like Q2. Roughly $23.4 billion of Cursor-related employee equity will run through comp over three years. Backlog is $63 billion, about $42 billion expected within twelve months. Compute stood at 1.7 GW at quarter end, with 2.5-3.0 GW targeted by year-end and 10 GW-plus in 2027. KeyBanc stayed Sector Weight on free cash flow pressure, and Musk said Terafab aims for a first test chip around May or June 2027 with volume production targeted Q3 2028.

Analyst targets and options flow

The sell side moved in a cluster, with a very wide spread. JPMorgan's Doug Anmuth more than doubled his target to $500 from $240 at Overweight; Pivotal went to $260 from $230 on Buy, lifting its 2027 revenue forecast to $168 billion from $118 billion and its 2027 capex assumption to $320 billion from $186 billion, with a doubled $225 billion capital-raise assumption. TD Cowen went to $224 from $200, Goldman to $245, Cantor to $345, Needham held $250, Stifel $190, Piper Sandler stayed Neutral at $140, and Susquehanna raised to $176 at Neutral. Headlines also carry Morgan Stanley $300, Wells Fargo $274, Citi $240 with a 90-day upside catalyst watch, UBS $230, and Raymond James at Strong Buy with $800. Options volume hit 2.17 million contracts by midday, 60% calls, put-to-call around 0.65, with genuinely new positions in the April $215 calls and a Sept 2027 $290/$300 call spread. Three-month implied vol fell 0.90 points to 49.40% even as the stock rose.

Merger talk and the Skydance angle

Musk confirmed that Tesla and SpaceX have each formed special committees of independent directors to explore a combination, with him recused as a conflicted party. He explicitly said no terms have been agreed and that calling a deal certain would be "overstating it", noting Tesla would need approval from 50% of all shares outstanding, not just votes cast. Kalshi contracts price a 42% chance of a merger by March 2027 and 77% before 2028; Polymarket has 20% by end-2026 and 68% by end-2027. Separately, John Malone told the Paley summit he expects a global output deal plus an $8-10 billion SpaceX investment into Skydance to delever it, pointing to Larry Ellison's history of financing Musk; SKYD was up 10.63% and carries nearly $87 billion of debt after the Warner Bros. Discovery deal closed this month. Two further spillovers: CoreWeave's market-implied bankruptcy odds through 2028 dropped to 14% on the back of SpaceX's numbers, and United Airlines flagged Starlink as part of its premium strategy, with the United CEO quoted saying customers are already switching airlines for it and over 50% of flights crossing to Starlink this week.

Netflix sells off on ads and margin

NFLX fell 5.3% on a Q3 that beat on earnings but came with soft current-quarter revenue guidance and a trimmed advertising outlook. These are all headline-only, but the direction of the analyst response is unambiguous and unusually uniform: Needham downgraded to Hold on slowing growth, and price targets were cut across Evercore to $90, BofA to $90 on engagement concerns, Wedbush to $80, Guggenheim to $78 on the ad revenue miss, Rosenblatt to $71, plus cuts from Bernstein, Canaccord and Pivotal. BMO, TD Cowen, KeyBanc, Citizens and William Blair kept their ratings. One headline notes a new 52-week low.

Smaller movers

TeraWulf rose 6.3% and Credo 6.2%, the latter attributed in the headline to AI memory momentum and a $235 target. Vertiv was up 4.4% on an Nvidia design headline, Vicor 4.4% on a Zacks "Bull of the Day" piece, NetApp 3.5%, and Kodiak Gas Services 3.3% on news its CEO joined Reworld's board. Elsewhere the moves are under 3% and the items are routine: analyst target tweaks on Incyte, Coherent, Oscar/SMR, Revolution Medicines and Nebius, a BioCryst FDA clearance for an Orladeyo oral pellet, a Planet Labs NASA task order to evaluate Tanager hyperspectral data, an Accenture downgrade to Neutral at Baird after a near-100% rally, and a long run of mechanical ETF flow notices around Apple, Broadcom and Costco that carry no new information.

Tower Semiconductor drops 8.2%

TSEM was the biggest mover on the list, down 8.2% to close at $183.78 on October 20. The GuruFocus piece covering it offers no company-specific news behind the fall, only valuation framing: the stock sits 238.1% above the GF Value estimate of $54.35, trades at a trailing P/E of 72.5x against a five-year median of 24.5x, with a forward P/E of 26.8x. Its GF Score is 77/100, strong on financial strength, profitability and growth at 8/10 each, but 1/10 on valuation. Insiders sold $60 million of stock over the past twelve months with no buying. The 52-week range is $71.64 to $319.94, so this is a name that has already travelled a long way in both directions.

Vicor up 7.1% on record quarter

Vicor rose 7.1% to $204.14 and has the most actual substance behind it today. Q3 2026 revenue was $197.1 million, up 37.5% sequentially and 78.5% year over year. Advanced Products contributed $138.9 million (up 47.5% sequentially), Brick $58.3 million, and royalty revenue was $66.6 million, up 119.1% sequentially, partly from a non-recurring payment by a new licensee. Gross margin jumped to 68.3%, a 1,030 basis point sequential gain, driven by the royalty mix and better product margins. Net income was $63.3 million, GAAP diluted EPS $1.33, cash $513.1 million, one-year backlog $406 million and book-to-bill above 1. Legal expense rose about $11.1 million to $16.1 million, tied to contingent costs on royalties, and management expects legal to run near 20% of royalty revenue. For Q4 the company guided to roughly 10% sequential product revenue growth and at least $43 million of royalties assuming no new licences, declining to give a full total because of uncertainty over licence timing. CEO Patrizio Vinciarelli said capacity is the near-term constraint: Fab 1 is land-limited, two new sites (ChiP Fab-2 and Fab-3) have been bought, initial Fab 2 equipment arrives in Q2 2027, and the combination could raise capacity nearly fivefold, funded without raising capital. He said one major customer described demand doubling annually for several years, mostly AI-related. Separately, a GuruFocus valuation note flags the stock at 181.6% above its GF Value of $72.49, with a GF Score of 79/100, trailing P/E of 65.5x (below the five-year median of 73.6x), forward P/E 33.4x, and $424.1 million of insider selling in the past year with no buying. Worth noting the context in that piece: the stock fell 23.6% in the prior week and is up 86.3% year to date. There is also a headline-only Nasdaq item naming Vicor as Zacks' Bull of the Day.

Adobe up 3.9%, valuation note only

Adobe rose 3.9% to $256.73. The only item is a GuruFocus valuation piece with no news driver: the stock sits 52.2% below the GF Value estimate of $536.75, trades at 14.3x trailing earnings versus a five-year median of 37.1x, forward P/E 9.3x, and carries a GF Score of 88/100 with 10/10 for both profitability and growth but 2/10 on valuation. Insiders were net sellers of $48.8 million over the past year.

Three mid-single-digit movers with thin news

RGNX was up 3.5% and the only item is the transcript of an investor event held October 20, but the text available is just the opening remarks, which mention RGX-314 being near top-line data. Nothing substantive beyond that. DLO rose 3.1% to $15.18, again on a valuation note rather than news: GF Score 94/100 with growth at 10/10, price 26.5% below the GF Value of $20.65, trailing P/E 22.2x against a five-year median of 29.7x, and $16.0 million of net insider selling over twelve months. INTU gained 3.0%; a GuruFocus DCF piece puts earnings-based intrinsic value at $394.87 against the $335.29 price, with an FCF-based figure of $887.39 and GF Value of $833.51, built off current EPS of $17.25, a 16.7% ten-year growth assumption and a 12% discount rate. The same article notes the stock is down 48.7% year to date but up 11.2% over the past week.

AMC ticker is pointing at the wrong company

Three items tagged AMC (+3.4%) are all about Aditya Birla Sun Life Asset Management in India, not the US name — worth knowing before you act on that move. Q2 FY27 revenue rose about 4-5% to INR 526 crore, profit before tax fell 6.3% to INR 296 crore and profit after tax fell 8.3% to INR 221 crore, with the squeeze coming from a 33% jump in employee costs to INR 1,263 million on ESOP charges, wage inflation and hiring in the passive business. Total average AUM crossed INR 11.06 lakh crore, up 140% year over year, but that was driven almost entirely by a INR 6,528 billion EPFO mandate; core mutual fund QAAUM grew only 4% to INR 4,418 billion. ETF AUM rose 42% against industry growth near 27%. Management said costs should stay around Q2 levels and plans six new fund launches. The shares were quoted down 1.32% at 946.05 in that coverage.

Comcast DCF note

CMCSA rose 2.1%. A GuruFocus DCF piece puts earnings-based intrinsic value at $41.26 versus the $22.36 price, and an FCF-based value of $81.45, with GF Value at $36.77. Inputs are current EPS of $3.16, 8.1% ten-year growth, 12% discount rate. The caveat the article itself raises is a GF Score of 66/100 and a predictability rank of 2/5, which makes the DCF less reliable. The stock is down 15.9% year to date.

NuScale downgraded by Barclays, hits 52-week low

SMR fell 1.9%. Barclays analyst Christine Cho cut NuScale from Equal Weight to Underweight with a $5 target, down from $11, and the stock touched an intraday 52-week low of $5.33. The stated reason is slow contract progress, specifically the unresolved power purchase agreement with the Tennessee Valley Authority, which could push negotiations into 2027 and delay revenue recognition. The company remains unprofitable with TTM EPS of -$2.28, so there is no meaningful P/E; price-to-sales is around 87.8x versus a historical median near 52x, and GF Value is $3.71. GF Score is 47/100, strong on financial strength (8/10, current ratio 37.88, no debt) but 0/10 on both profitability and growth, with revenue down 6.2% over three years.

Netflix down 1.7% on soft guidance, heavy analyst cluster

There are over forty NFLX items and nearly all are headline-only, but the shape is consistent. Netflix beat Q3 earnings expectations and then fell, with the stated cause being cautious advertising and revenue guidance for Q4. Headlines list target cuts and rating changes from Pivotal Research (subscriber concerns), Guggenheim (ad revenue miss), Canaccord (execution concerns), Bernstein (2027 uncertainty), Bank of America (target to $90), Needham (downgraded to Hold), with maintained ratings from KeyBanc, Citizens, William Blair, and Wedbush's Ives at In Line and $75. The one Netflix item read in full is the Needham downgrade write-up, which says Laura Martin moved the stock from Buy to Hold on a more cautious view of growth amid competitive pressure, and notes a price of $68.69 against GF Value of $103.48, a trailing P/E of 21.64x versus a five-year median of 40.38x, a GF Score of 90/100 with profitability and growth both 10/10 but momentum at 2/10, and $13.2 million of insider selling in three months. Several headlines also reference a content leadership restructuring and a 52-week low.

Musk merger talk and the SpaceX block

SpaceX is flat on the day at -0.1% despite being the single largest item cluster on the list, almost all headline-only. The one full-text item, a GuruFocus morning brief, reports Musk confirming he is considering merging Tesla and SpaceX with both companies forming special committees, and SpaceX posting a 161% year-over-year revenue rise and a $4.4 billion quarterly profit on Starlink and AI growth. The same brief notes Boeing's 737 Max 10 received FAA certification, France's 10-year yield passed 5% for the first time since 2002, UK CPI rose to 3.5%, Anthropic reported a net loss above $80 billion for H1 2026, Micron settled its Taichung labour dispute in Taiwan, and Japanese export growth slowed to 16.7%. Headlines around SpaceX include large target increases (JPMorgan to $500 from $240, Goldman to $245, Cantor to $345) and a recurring Starlink-Ukraine access dispute. Given the quote shows no move, this is reading material rather than a trigger.

Smaller movers and the quiet remainder

ASTS was down 1.8% on an 8-K filing covering officer departures or appointments and compensatory arrangements — administrative, no detail in the filing summary. Cantor Fitzgerald initiated Modine Manufacturing at Overweight (MOD, -1.9%), headline only. Upstart was up 1.7% alongside an 8-K covering a material definitive agreement and a new direct financial obligation, with no further detail given. Beyond that the section is quiet: Micron (-1.0%) has the Taiwan labour agreement plus a $25.7 million stock sale by Scott Deboer, Accenture (+0.9%) was downgraded by Baird to neutral on valuation with the target raised to $252 and separately announced a physical AI safety suite with TUV SUD, and the remaining names are routine ETF flow notes, 13F-style buy/sell summaries and technical chart posts that carry no new information.

Revolution Medicines starts Phase 3 in lung cancer

RVMD is up 7.9% after announcing it has begun dosing patients in RASolve 308, a global Phase 3 trial of zoldonrasib, its oral RAS(ON) G12D-selective inhibitor, combined with pembrolizumab and platinum chemotherapy as first-line treatment in metastatic RAS G12D non-squamous NSCLC. The trial is randomised and double-blind against placebo plus the same standard regimen, with progression-free survival as the primary endpoint and overall survival, response rate, duration of response, safety and patient-reported outcomes as secondaries. The company frames the opportunity as a population with no approved targeted option: RAS G12D shows up in roughly 4% of NSCLC cases, against more than 229,000 US lung cancer diagnoses a year, and Revolution estimates about 61,000 new US patients annually across all RAS G12D cancers. Chief development officer Alan Sandler said earlier combination data showed encouraging preliminary antitumor activity and a favourable safety profile.

Eos Energy reaffirms, stock down anyway

EOSE is down 7.2%. The only item on it is a guidance roundup noting Eos reaffirmed fiscal 2026 revenue of $300 million to $350 million, unchanged from the range given on 5 August. Nothing in that piece explains the drop; it simply records the reaffirmation alongside Crown Holdings issuing new Q4 adjusted EPS guidance of $1.63 to $1.73.

Vicor Q3 blowout, record backlog, capacity build

Vicor is up 7.1% and is by far the most documented name here. Q3 revenue was $197.1 million, up 78.5% from $110.4 million a year ago and 37.5% sequentially, beating the roughly $183.7 million consensus. Royalty revenue was the swing factor, more than tripling to $66.6 million from $21.7 million, with product revenue at $130.5 million. Gross margin went to 68.3% from 57.5% a year earlier, and net income more than doubled to $63.3 million, or $1.33 a share. On EPS the reporting is inconsistent: Investing.com called $1.33 a beat against a $1.29 consensus, while GuruFocus framed it as a miss versus $1.37. Backlog rose 166% year over year to $406 million, up 7% sequentially, and the company flagged $100 million of bookings in the first half of Q4. Operating cash flow was $69.7 million against $38.5 million a year ago, and cash ended at $513.1 million, up 13.1% sequentially. CEO Patrizio Vinciarelli said the purchase of two additional sites within 30 miles of ChiP Fab-1 in Andover will give nearly a 5x capacity increase across three fabs. On the licensing side, Vicor granted its first Vertical Power Delivery licence to an AI OEM at Stage-2 unit royalty rates, and said the ITC's decision to open an investigation into VPD infringement is drawing licence enquiries from unlicensed OEMs and hyperscalers. Operating expenses rose to $62.5 million from $48.2 million, partly on contingency fees tied to that IP effort. Needham's N. Quinn Bolton reiterated Buy with a $350 target on 1 October, and Investing.com put the consensus target near $391.67 with EPS estimates revised up over 53% in the prior 60 days. Against that, GuruFocus repeatedly flags its own GF Value of $72.49 versus a price around $190 to $202, and notes $424.1 million of insider selling over twelve months with no insider buying, plus six of seven tracked gurus trimming. The Q3 call transcript and the 8-K are also in the list.

Datavault AI presentation at LD Micro

DVLT is up 4.7% after presenting at the LD Micro Main Event. CFO Brett Moyer described the company as a platform facilitator that helps customers value, tokenise, exchange, store and convert assets without owning them, comparing the model to eBay. He said four exchanges are live with one more coming and about 14 contracts under execution across real-world assets and data monetisation, with revenue from technology fees, transaction fees, cybersecurity and political donation processing. Partners cited include IBM watsonx, NYIAX, Fiserv, CLEAR, Trulioo, Houlihan Lokey and Available Infrastructure, plus CyberCatch, acquired in May 2024. The caveats were in the same presentation: the BankWise custody acquisition still needs Wyoming Bank Commissioner approval and is 12 to 14 months from full operation, the Fiserv fiat-conversion integration has one step left, and regulatory treatment of tokenised real-world assets under the CLARITY Act remains unsettled, with a London Perpetuals exchange held as a fallback. Moyer said the Available Infrastructure contract was locked in at January 2024 pricing and would cost more than 100% more today given GPU prices.

Oracle software spending survey

Oracle is up 1.2% and appears in a BNP Paribas note read in full. Analyst Stefan Slowinski said Oracle's software spending indicators improved in October after weakening in July, with Europe recovering and the trailing three-month spending score rising more than expected. Oracle's database services sold through AWS and Microsoft ranked among the three most sought-after products, with OCI and Fusion also improving. AWS had the strongest reading overall. Generative AI overtook cybersecurity as the top spending priority, which Slowinski suggested may mean AI tools are moving from experiments into budgets. The same survey was weak for Adobe and Zoom, with IBM ranked last. Adobe is nonetheless up 3.9% today, with its other items being Form 4 filings from Shantanu Narayen, interim CFO Steven Day and two other executives.

Headline-only movers worth a glance

Several names moved on items only read as headlines. Forgent is down 4.1% on a piece comparing it with Eaton as a data centre power stock. Red Cat is down 3.4%; Needham reiterated it at a $15.00 target, and CEO Jeffrey Thompson sold $676,500 of stock. Incyte is up 3.0% with president Pablo Cagnoni selling $297,779. Exelixis is up 2.7% and hit an all-time high at $63.39. UiPath is up 2.4% after CEO and chairman Daniel Dines sold 2.5 million shares, reported as $33.07 million. NuScale is down 2.0% after Barclays downgraded it to Underweight and cut its target on execution risks, with a separate piece asking why the stock was down 6%. Modine is down 1.9% after Cantor Fitzgerald initiated at Overweight. AST SpaceMobile is down 1.8% and touched a 52-week low at $39.85, with other headlines on a 60-plus ground gateway buildout and European spectrum. Datadog is down 1.5% despite a Bernstein upgrade to Outperform with a $350 target citing AI demand. Netflix is down 1.7% into tonight's results, with options reportedly pricing a 10% move, BMO cutting its target to $125, and headlines on a creative leadership reshuffle.

Apple, SpaceX and the quieter names

Apple is down 1.0% on a busy but mostly headline-level flow. Loop Capital downgraded it to Hold with the target cut to $330 from $370, on supply chain checks suggesting Apple will not recover 13 million iPhone shipments cut from 2026 plans, and MoffettNathanson kept Neutral while lowering its target to $283. Offsetting headlines cover up to $100 million committed to US titanium supply and new domestic suppliers for the iPhone 18 Pro, a 28 October product event, and a UK CMA consultation proposing lower Apple Pay fees and wider access to iPhone contactless. SpaceX is essentially flat at -0.1% but carries the largest headline cluster in the list, all pointing at tonight's Q3 report, Starlink, AI revenue, a Falcon 9 Bandwagon-5 launch and recurring Tesla merger speculation. The rest, including Broadcom, TSMC, Micron, Accenture, NetApp, Nebius, Sandisk, Coherent, Silence Therapeutics and the various Form 4 filings, moved around a percent or less and the items on them are routine.

Silence Therapeutics taken out by Merck KGaA

Silence Therapeutics is up 125.6%, and the reason is clean: Germany's Merck KGaA has agreed to buy the company in an all-cash deal, about $1.3 billion in equity value and $1.1 billion enterprise value. Holders get $20.00 per ADS, each ADS being three ordinary shares. That is a 130% premium to Friday's ADS close and an 82% premium to the 30-day VWAP of $10.99. Chairman and interim principal executive Iain Ross described it as the result of a competitive sale process delivering immediate and certain value. The structure is a UK scheme of arrangement under Part 26 of the Companies Act, needs shareholder approval, sanction by the High Court in England and Wales and regulatory clearances, and is expected to close in Q1 2027. The board approved unanimously and holders of roughly 14% of voting power have signed support agreements. Merck is buying the RNA platform that silences disease-causing protein production: lead asset divesiran in polycythemia vera, plus zerlasiran for elevated Lp(a). GuruFocus makes the point that from here the remaining return is tied to deal completion rather than clinical data.

Memory names bounce back, SanDisk and Micron

SanDisk is up 5.5% and Micron up 3.0%, a recovery from last week's memory selloff rather than anything new on fundamentals. GuruFocus notes Nasdaq 100 futures were up about 1.2% and S&P futures about 0.7% premarket, with falling oil easing inflation and rate worries, plus renewed attention on Nvidia reportedly asking Micron, SK Hynix and Samsung to use TSMC's 3nm process for base dies in custom HBM. SK Hynix gained 4.1%. Average analyst targets cited imply roughly 80% upside for Micron, 70% for SanDisk, 87% for SK Hynix. Context on how far SNDK fell: a separate GuruFocus piece describes a 17.9% single-day drop on a hotter-than-expected CPI print that pushed the VIX up nearly 30% to a four-month high, against a 857.8% first-half gain. SNDK trades at 19.03x trailing earnings versus a five-year median of 23.74x, GF Score 45, insiders sold $131.6 million over twelve months with no buying. The competitive overhang is China's ChangXin Memory, which fell 7.77% in Shanghai despite guiding to nine-month 2026 revenue of 265-270 billion yuan against 32.08 billion a year earlier and net profit of 131-132.5 billion. Western Digital, which reports fiscal Q1 late Thursday, led the S&P 500 up 6.1% to 352.21 per IBD. One TradingView post flagged a systematic long bracket order on SNDK at 1371.12 off an RSI cross above 30, stop 982.07, target 2927.36 — that's a retail chart setup, not news.

Datadog upgraded at Bernstein on AI token demand

Datadog is up 5.4%, driven by Bernstein's Peter Weed upgrading to Outperform from Market Perform with the target lifted to $350 from $237, and FY26/FY27 EPS estimates moved to $2.82 and $4.00. The notable thing is that Bernstein is reversing its own downgrade from last quarter, which had cited roughly $100 million of ARR cut from Datadog's largest "Born in AI" customer and weakness in the traditional base that makes up about 85% of revenue. Bernstein had expected net new ARR growth to slow to 20-30% in 2027 from 80-90% this year. That slowdown hasn't appeared: alternative data shows enterprise token consumption at the largest AI labs grew at least 50% quarter over quarter, possibly faster at smaller AI-native customers, with consumer agent launches Muse and Dots cited. Jefferies went the other way, trimming its target to $280 from $300. Schaeffer's notes the move snaps a five-day losing streak after the October 12 record high of $300.68, with the stock up 93.5% year to date, 42 of 46 covering brokers at buy or better, and a 10-day put/call ratio of 1.11 in the 91st percentile. GuruFocus flags the counterweight: GF Value $206.84 against a price around $260, so roughly 26% overvalued, trailing P/E of 531x versus a five-year median near 420x, GF Score 83 with growth at 10/10 but profitability 4/10, and insiders selling $905.8 million over twelve months with no buying. Q3 results land November 4. A TradingView write-up covers the same tension, arguing stock-based compensation and dilution matter as much as free cash flow growth here.

Arista, Accenture and TeraWulf valuation screens

Arista is up 3.4% to $182.95, though still down 13.2% on the week and 8.2% on the month, with GuruFocus putting it 7.5% above GF Value of $170.16 on a 57.7x trailing P/E against a 42.7x five-year median, a near-perfect GF Score of 99, and insiders having sold $1.50 billion over twelve months with no buying. Accenture is up 3.2% to $236.93 and screens the opposite way, 32.5% below GF Value of $351.20, with a 17.5x trailing P/E versus a 27.2x median and GF Score 87, though insiders sold $19.1 million and bought nothing. TeraWulf is up 3.3% to $12.06 but GuruFocus calls it 102% above GF Value of $5.97, GF Score 39, growth 0/10, trailing P/E of 180x against a 21.2x median, and net insider selling of $35.6 million over the year. Separately and headline-only, Accenture is reported to be eyeing a $1.5 billion exit in a key market as its AI strategy shifts.

Headline-only movers worth a glance

Several names moved on things I only have the headline for. NuScale is down 2.4% after Barclays downgraded it to Underweight and cut the target on execution risks, with a separate piece asking why the stock was down 6% intraday. Apple is down 0.2%, with Loop Capital downgrading to Hold and cutting its target to $330 from $370, the stated reason being that supply chain checks suggest Apple won't recover 13 million iPhone shipments cut from 2026 plans; separately Apple has set a product event for October 28 and committed up to $100 million for US titanium. AST SpaceMobile is up 3.0% on a European satellite spectrum collaboration. Nebius is up 2.9% alongside a broader neocloud rebound and a Truist $355 call. Revolution Medicines is up 2.4% having started a Phase 3 lung cancer trial, with Truist raising its target to $241. UiPath is up 2.1% despite CEO Daniel Dines selling 2.5 million shares for $33.07 million and Hedgeye naming it a top short. SpaceX is up 1.3% ahead of Q3 earnings, with heavy flow around Musk's pledge to gift SpaceX stock to children via Trump Accounts and Kalshi pricing a Tesla-SpaceX merger before February 2027 at 67%, up from about 30% earlier this month. Netflix is down 1.0% into tonight's after-close report, consensus EPS $0.82, amid back-to-back senior departures including film chief Dan Lin. Vicor is essentially flat at -0.4% after a Q3 earnings beat that reportedly sent shares up 5%.

Oil backdrop behind the tape

One item tagged to SLN is actually an OilPrice opinion piece by James Durso arguing a US ground invasion of Iran would be a strategic catastrophe, pointing to Iran's size, terrain and IRGC asymmetric preparations, and saying an invasion could push oil toward $200 a barrel. It has nothing to do with Silence Therapeutics, but the surrounding price board is relevant to the day: WTI around 100.5 and Brent around 111, up on tanker attacks in the Persian Gulf, Asian LNG past $30, and Canadian inflation at 3.1% with fuel oil up 58%. Falling oil in the US session was cited as part of why tech bounced.

Silence Therapeutics taken out by Merck KGaA

Silence Therapeutics is up 125.6% after agreeing to an all-cash takeover by Germany's Merck KGaA at $20.00 per American depositary share, each ADS representing three ordinary shares. That values the equity at roughly $1.3 billion and the enterprise at about $1.1 billion, and works out to a 130% premium to Friday's close and an 82% premium to the 30-day volume-weighted average of $10.99. Chairman and interim principal executive Iain Ross described it as the result of a competitive sale process delivering immediate and certain value. Merck is buying Silence's RNA platform, which silences production of disease-causing proteins; lead programme divesiran targets polycythemia vera and zerlasiran targets elevated lipoprotein(a). The structure is a UK scheme of arrangement, the board approved unanimously, and holders of about 14% of voting power have signed support agreements. Closing is guided for the first quarter of 2027, subject to shareholder approval, sanction by the High Court in England and Wales, and regulatory clearances. GuruFocus makes the point that the remaining upside is now tied to the deal closing rather than to clinical results. There is also an 8-K on file covering the material agreement.

OpenWorld falls on Blocksight merger news

OpenWorld is down 18.4% despite announcing a definitive merger agreement to acquire Blocksight Holdings, which builds AI agents that automate real-world asset tokenization — deal structuring, asset data verification, investor onboarding, daily reporting and servicing, with human sign-off at key decision points. The acquisition was first flagged on October 1 and the agents are to be folded into OpenWorld Enterprise. CEO Matt Shaw said programmes of that size cannot be verified and reported on by hand. Blocksight co-founders Patrick Kim and Peter Hong are expected to join on closing. Since the October 1 announcement OpenWorld signed two non-binding term sheets: one on October 7 with BeyondAI for an IP-backed transaction of up to $130 million, tokens representing rights to payments backed by patents and software rights, and one on October 15 with Meridian for a tokenized financing programme of up to $1 billion funding a distributed AI computing network run on solar and residential battery storage, initial deployment of 10,000 homes, with Meridian holding purchase rights to Tesla Powerwall systems and first installations due in Q4 2026 and a first commercial site in Q1 2027. Both term sheets are non-binding and the merger is still subject to customary closing conditions. None of the articles explains the share price drop. An 8-K covering the agreement and an unregistered equity sale is also on the list.

Memory names rebound after last week's selloff

SanDisk is up 5.7% and Micron up 3.0%, part of a broad memory bounce after a rough week. GuruFocus reported Micron up about 5% and SanDisk about 4% intraday, with SK Hynix adding 4.1%; Nasdaq 100 futures had been up nearly 1.2% and oil prices fell, easing inflation and rate pressure. The piece also notes renewed attention on Nvidia reportedly asking Micron, SK Hynix and Samsung to use TSMC's 3nm process for base dies in custom HBM, and cites average analyst targets implying roughly 80% upside for Micron, 70% for SanDisk and 87% for SK Hynix. The bear side is unchanged: scrutiny of AI infrastructure spending returns, and China's ChangXin Memory is pushing into DRAM — CXMT fell 7.77% in Shanghai even while guiding nine-month 2026 revenue to 265-270 billion yuan against 32.08 billion a year earlier and net profit of 131-132.5 billion yuan, reversing a prior-year loss. Separately, a GuruFocus piece covering last week's 17.9% SanDisk drop blamed a tech selloff on a hotter-than-expected CPI print, with the VIX up nearly 30% to a four-month high; it lists SanDisk's trailing P/E at 19.03x versus a five-year median of 23.74x, a GF Score of 45, $131.6 million of insider selling over twelve months with no buying, and a first-half gain of 857.8%. ETF flow data for October 15 shows net buying of $28.3 million in SNDK across 41 buyers and 16 sellers, led by DUHP at $37.5 million. There's also a headline-only Nasdaq "Bull of the Day: Sandisk" piece.

Datadog up on Bernstein upgrade

Datadog is up 5.3% after Bernstein SocGen's Peter Weed upgraded it to Outperform from Market Perform and lifted the target to $350 from $237. Bernstein had downgraded last quarter over a roughly $100 million ARR contract downsizing at Datadog's largest "Born in AI" customer, believed to be OpenAI, plus late-year softness in the traditional customer base that makes up about 85% of revenue, and had modelled net new ARR growth slowing to 20-30% in 2027 from 80-90% this year. That slowdown hasn't appeared: the firm's alternative data now shows enterprise token consumption at the biggest AI labs up at least 50% quarter over quarter, possibly faster at smaller Born in AI customers, helped by consumer AI agent launches Muse and Dots. Context matters here — the stock had fallen about 14% over the prior week from its October 12 record of $300.68, and today snaps a five-day losing streak. Jefferies trimmed its target to $280 from $300, while Mizuho had earlier raised to $330. Of 46 brokerages, 42 rate it buy or better against three holds and one strong sell. Schaeffer's notes a 10-day put/call ratio of 1.11, in the 91st percentile of its annual range, and a Volatility Scorecard of 84. GuruFocus flags the valuation side: GF Value of $206.84 against a price around $263.85, trailing P/E of 538x versus a five-year median of 419x, GF Score 83, and $905.8 million of insider selling over twelve months with no purchases. Q3 results are due November 4.

SpaceX headlines dominated by Musk share pledge and merger talk

SPCX is up 1.3% on a heavy but headline-only news flow. Musk posted that he will give one of his SpaceX shares to every kid in America next year, with one summary putting the implied total at roughly $10.7 billion across about 73 million children at $146.03 a share, and another headline saying the gift would be distributed via Trump Accounts. Separately, Tesla-SpaceX merger speculation picked up: one item cites Kalshi pricing a 67% chance of a merger before February 2027, up from around 30% earlier in the month, after a Tesla SEC filing revealed SpaceX board ties and change-of-control provisions, and Barclays analysts are said to anticipate an announcement before the December meeting. RBC reiterated its rating on a spectrum purchase. Tesla's redesigned Roadster, using SpaceX technology, and a Starlink Ukraine service controversy also feature. Earnings are coming and are framed as a test of Musk's AI spending ambitions.

Neoclouds and AI infrastructure bounce

Nebius is up 3.0%, part of the same rebound — one wire headline has CoreWeave up 6%, Nebius up 7% and IREN up 5.7% premarket, and another groups CoreWeave, Applied Digital, Nebius and IREN recovering after the AI selloff. Truist has a $355 call on Nebius which one headline frames as facing a cash-funding test, a director sold 7,260 shares, and November puts had surged 48% with shares at $165.47. Nvidia-backed Nscale's IPO is reported to be meeting valuation pushback. All headline-only.

Accenture and other mid-single-digit movers

Accenture is up 3.2% on two threads: a reported $1.5 billion sale of its Greater China unit, framed in the headlines around AI concerns, and an Accenture Federal partnership with Google to launch an AI agent deployment programme. Arista is up 3.3% with only a Form 4 filing and a DCF piece behind it, nothing with real content. WULF is up 3.3% on a technical post only. AST SpaceMobile is up 2.9%, with several outlets tying it to a European satellite spectrum collaboration and broadband push. TSMC is up 2.0% alongside headlines on new 3nm production at Kumamoto, Samsung's move for Nvidia chips, and JPMorgan ending a bearish Intel call held since 2022. Revolution Medicines is up 2.4% after Truist raised its target to $241, and Exelixis has a Citizens target raise to $65 on ESMO data.

Netflix into earnings

Netflix is down 1.0% ahead of its third-quarter report, with headlines centred on whether tone and guidance matter more than the beat, questions over user engagement, and the dismissal of film chief Dan Lin — the second senior content departure in a week. Headline-only throughout.

Apple quiet on price, noisy on flow

Apple is essentially flat at -0.1% but carries the longest headline list here, and it cuts both ways. A second October event is set for the 28th in LA, expected to feature new MacBook Pro models, an M6 chip and reportedly Apple's first touch-screen MacBook, with another item pointing to a November 6 launch including iMac. On demand, KeyBanc reiterated Underweight with a $250 target after surveying 2,046 iPhone users, warning higher prices and longer upgrade cycles could sap iPhone 18 momentum, and Jefferies flagged deteriorating Pro and Pro Max demand with China lead times at zero and reported component order cuts of 10-15%. Against that, JPMorgan reiterated Overweight on demand trends and Melius kept Buy with a $370 target, calling the rally to $5 trillion one nobody liked. Much of the rest is routine ETF rebalancing detail. All headline-only.

The rest

Red Cat is down 1.2% with a tender offer for Steyr Motors in the headlines, Steyr up 20% premarket and Clear Street backing the deal. PayPal is down 0.5% after a Cleveland Research downgrade on weakening trends. Joby is down 1.3% after Morgan Stanley cut its target to $10. Vicor reports Q3 shortly. Beyond that the list is filings, DCF screens and ETF flow notes with no real movement attached.

What the numbers in brackets are measuring

A caution before anything else: the bracketed moves are Friday's October 16 close, a broad AI-infrastructure selloff day, while several of the full articles below are dated October 19 and describe pre-market bounces off those lows. So Nebius shows -12.2% here and simultaneously has three pieces titled "Why is Nebius stock rallying today?" Both are true, just on different clocks.

Vicor down 12.9%

Vicor was the largest faller, down 12.9% to $191.50. The GuruFocus piece covering it is a valuation screen rather than news: no operating event is given for the drop. Their model puts fair value at $72.20 against that $191.50 price, a 165% premium, with a GF Score of 81/100 that pairs a growth sub-rank of 9/10 against a valuation rank of 1/10. Trailing P/E is 61.5x versus a five-year median of 74.0x, forward P/E 31.3x. Insiders sold $424.1m of stock over the past twelve months with no purchases. The 52-week range is $57.00 to $382.65.

Nebius and the neocloud unwind

Nebius is the densest story in the list, down 12.2% to $165.47 on Friday with volume around 31-35m shares, roughly 1.7x its monthly average, its sixth decline in eight sessions and on top of a 10% loss earlier that week. That was a sector move, not a company one: CoreWeave fell 11.9% to $61.39 the same session and lost about a quarter of its market value over the week on debt concerns, IREN fell 11.2%, and Nebius is down roughly 21-32% over the prior two weeks depending on which window the piece uses. The trigger behind the sector reassessment is laid out in the Nscale article: the Nvidia-backed London data centre developer is facing pushback on its roughly $30bn US IPO target, with investors arguing $16-19bn is more realistic, citing the collapse of Australian AI data centre firm Firmus's IPO plan. Microsoft, both investor and client, has pulled out of a UK data centre deal with Nscale after power constraints delayed the site, and its flagship Norway facility is six months behind schedule. Nscale filed publicly on September 18 and raised $3.36bn pre-IPO last month led by Third Point, with Nvidia, Apollo and Citadel participating.

What pushed Nebius back up Monday

By Monday pre-open Nebius was up 3.6%. Investing.com attributes it to a Truist note published Sunday evening reiterating Buy on both Nebius and CoreWeave with a $355 target on NBIS, arguing the Firmus collapse is not a read-across for providers with contracted backlogs and that Nebius's projected 4.5x 2028 EV/Sales is justified by above-average revenue growth. Alongside that, Nebius announced a $10m programme for European AI developers offering compute grants and capital access, with NVIDIA and Accel. Director Arne Grimme bought 296 shares at $169.99 on October 16, taking him to 6,181 shares; note the context, there has been one insider buy against 33 insider sells in the past year, totalling $318.2m sold. Earnings are scheduled for October 22. Two more sceptical pieces are in the list: GuruFocus flags a P/S of 34.12 against a historical median of 7.0, GF Score 52/100, negative EPS of -$0.13 and an Altman Z of 2.33, while a TradingView author focuses on the roughly $8.55bn of debt funding the 600MW Rotterdam build and the gap between $1.36bn of revenue and a 3.1% net margin and 0.4% ROE. A separate chart piece marks $234-240 as resistance and the weekly 50 EMA as support. Treat the TradingView items as individual opinion, not reporting.

Rocket Lab, Neutron slips to 2027

Rocket Lab fell 8.0% to $50.84, its eighth straight down day after drops of 8% and 7%. The cause is specific and company-level: on October 14 Rocket Lab said the Neutron rocket's debut is pushed into 2027 after air pockets were found in the propellant-tank dome, requiring a redesign and further testing. The underlying business is still growing, with Q2 revenue around $234m, up 62% year on year, backlog of $2.36bn, and a net loss of roughly $49m. GuruFocus puts P/S at 38.78 against a historical median of 18.88 and GF Value at $39.19, scoring it 77/100 with growth 10/10 and profitability 3/10. Insiders sold $683.3m over twelve months with no purchases, nine sells in the last three months. Two TradingView pieces take opposite sides, one mapping a path toward $40 and two headline-only posts framing the drop as a discounted entry.

Xometry down 8.7%

Xometry fell 8.7% to $90.91, again with no operating news attached. GuruFocus has GF Value at $48.11, an 89% premium, GF Score 71/100, forward P/E 70.5x, and net insider selling of $15.9m over the year ($4.0m bought, $20.0m sold). There is also a Form 144 filed October 17, which the article body does not detail beyond the filing itself.

AST SpaceMobile, European spectrum consortium

ASTS closed down 8.5% on Friday, having touched a 52-week low of $39.87, then rose 3.5-3.9% Monday pre-open. The substance: Deutsche Telekom, Orange, Telefónica and Vodafone signed a Letter of Intent to explore a joint bid for Mobile Satellite Services spectrum, covering a European market of over 500m subscribers, with AST providing European-operated ground infrastructure linking its BlueBird satellites to operator core networks and keeping data handling inside European jurisdiction. AST cites demonstrated peak downloads of 98.9 Mbps, next-generation satellites targeting close to 200 Mbps, and tuning across roughly 1,150 MHz of partner low- and mid-band spectrum plus its S-band priority rights. Separately, Boost Mobile founder and MobileX CEO Peter Adderton said publicly he bought near $40 and argued carriers may look to acquire AST or fold it into a consortium as a hedge against SpaceX. The 52-week high is $133.86 and the stated consensus rating is Hold.

Aurora and the Form 4 items

Aurora Innovation is shown down 10.1%, and the only item behind it is a Form 4 for director David Wehner dated October 1. The article carries no share count, price or reasoning, so there is nothing explaining the move. Same pattern across a batch of other names: Form 144s or Form 4s at Micron, Joby, Generac, Oracle, Apple, Broadcom, Credo, Kodiak, Take-Two, PayPal, NuScale and Mercury, all filing-notice headlines with no detail attached.

Iran headline, mis-tagged ticker

One item tagged to CAN (-8.2%) is actually a Walter Bloomberg post relaying Iran's foreign minister saying the Strait could open within six days if the US meets Iran's conditions, with talks resuming on the seventh day, sourced to a Telegram channel. It has nothing to do with the ticker it's filed under, and the replies to the post are openly sceptical of it. Relevant only as an oil-tape input.

Semis and large-cap tech, mostly headline-only

The semi and AI complex fell as a block and most of it is headline-level: Micron -5.6% with a headline tying it to the Nasdaq tech selloff, SanDisk -6.8%, Tower Semiconductor -6.8%, Credo -4.9%, Broadcom -4.5%, Oracle -4.6%, Arista -4.6%, Datadog -7.2% (where a Bernstein upgrade on AI demand strength is noted in a headline), TSMC -2.3%, Amphenol -2.6%. The one full-text item on the theme is a Japan wrap: the Nikkei 225 closed down 0.58% at 64,948.04, with Tokyo Electron -2.35% at ¥10,380 and SoftBank -1.31% at ¥4,879, Deutsche Bank attributing the move to investor anxiety over AI investment sustainability spilling over from Wall Street. Several GuruFocus DCF headlines sit alongside these, all flagging intrinsic values well below market, and they are headline-only valuation screens rather than news.

Smaller names with actual events

OpenWorld, down 7.3%, filed an 8-K and headlines say it signed a merger deal to acquire AI agent firm Blocksight, with a second 8-K covering officer and bylaw changes; no terms are visible from the headlines. Red Cat, down 3.7%, has headlines on a tender offer for Steyr Motors (Steyr shares reportedly up 20% pre-market) and a new long-endurance Trichon drone. Planet Labs fell 6.7%, with a director sale by Kristen Robinson of $565,560 and a Form 144. Beam Therapeutics fell 5.1% with CEO John Evans selling $1.19m. Silence Therapeutics, down 7.2%, filed an 8-K covering a material definitive agreement. William Blair initiated Revolution Medicines at Outperform; the stock closed down 6.0%. Citizens raised its Exelixis target to $65 on ESMO data.

SpaceX, Musk and the Tesla merger chatter

SPCX closed down 1.7% and carries the largest headline cluster in the list. Musk posted that he will give one SpaceX share to every child in America next year; a derived figure in one headline puts that at roughly 73m children at $146.03 a share, about $10.7bn. Other headlines cover Tesla's flying Roadster unveiling using SpaceX technology, Barclays analysts anticipating a Tesla-SpaceX merger announcement before the December meeting, Ukraine imposing speed limits on Starlink networks, and 24 ETFs adding to SPCX on October 15. All headline-level.

Apple and Netflix

Apple closed up 0.4%, the one green large cap, with a heavy but thin item load: JPMorgan reiterating Overweight on iPhone demand trends, a November 6 product launch including MacBook Pro and iMac, reported strong iPhone pre-orders with shipping slipping to January 2027, a new VP of global litigation, plus a long run of ETF flow notes. Netflix fell 2.9% ahead of its Q3 report this week, with one headline flagging questions on user engagement and another on a leadership reshuffle. Tesla, Meta, IBM and Spotify also report this week per the earnings-calendar posts, which is the backdrop several of the technical pieces above are positioning around.

The rest

Accenture was up 2.1%, with headlines on an AI agent deployment programme with Google Federal and a reported consideration of a $1.5bn sale of its Greater China unit. Everything else in the list, including Costco, Comcast, Paychex, Modine, Sezzle, SoundHound, Incyte, Avery Dennison and the SLV chart posts, moved less than a couple of percent or is chart commentary with nothing new behind it.